Soft Tissue Sarcoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 224 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Soft Tissue Sarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Soft Tissue Sarcoma - Pipeline Review, H2 2014', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Soft Tissue Sarcoma - Overview 11
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12
Soft Tissue Sarcoma - Therapeutics under Development by Companies 13
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 15
Soft Tissue Sarcoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Soft Tissue Sarcoma - Products under Development by Companies 20
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 22
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 23
A. Menarini Industrie Farmaceutiche Riunite Srl 23
Activartis Biotech GmbH 24
Advenchen Laboratories, LLC 25
Amgen Inc. 26
Bayer AG 27
Boehringer Ingelheim GmbH 28
CASI Pharmaceuticals Inc. 29
Celgene Corporation 30
CytRx Corporation 31
Eli Lilly and Company 32
Exelixis, Inc. 33
Gem Pharmaceuticals, LLC 34
GP Pharm, S.A. 35
Karyopharm Therapeutics, Inc. 36
MedImmune, LLC 37
Merck & Co., Inc. 38
MolMed S.p.A. 39
Morphotek, Inc. 40
Nanobiotix 41
Novartis AG 42
Oncos Therapeutics Ltd. 43
Onxeo SA 44
Pharma Mar, S.A. 45
Polaris Group 46
Recombio S.L 47
Sigma-Tau S.p.A. 48
Telik, Inc. 49
Threshold Pharmaceuticals, Inc. 50
Soft Tissue Sarcoma - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AL-3818 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
aldoxorubicin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AV0-113 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
belinostat - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BI-853520 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
cabozantinib s-malate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
celyvir - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
doxorubicin liposomal - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
durvalumab + tremelimumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ENMD-2076 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
everolimus - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
evofosfamide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ganitumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
GPX-150 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
MVX-ONCO-1 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NBTX-TOPO - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
NBTXR-3 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
NGR-hTNF - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
olaratumab - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
ONCOS-102 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
ontuxizumab - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
paclitaxel albumin bound - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
panobinostat - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
regorafenib - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
ridaforolimus - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
sabarubicin - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
selinexor - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
SST-0001 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
TNF-PEG 20 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
trabectedin - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Vaccine for Cancer - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Vaccine for Sarcoma - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Soft Tissue Sarcoma - Recent Pipeline Updates 145
Soft Tissue Sarcoma - Dormant Projects 211
Soft Tissue Sarcoma - Discontinued Products 212
Soft Tissue Sarcoma - Product Development Milestones 213
Featured News & Press Releases 213
Oct 20, 2014: CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society 213
Oct 17, 2014: CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 214
Oct 16, 2014: Nanobiotix Receives First Approval To Start Phase II/III Registration Trial In STS In Europe 215
Oct 08, 2014: PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma 216
Sep 22, 2014: CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 217
Sep 22, 2014: Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis 218
Aug 07, 2014: Oral Presentation of CytRx's Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology 219
Jun 04, 2014: PharmaMar's partner Taiho Pharmaceutical presents at ASCO the results from the Phase 2 clinical trial of Yondelis in patients with Malignant Soft Tissue Sarcoma 220
Jun 02, 2014: Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO 221
May 28, 2014: CytRx Highlights Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma 221
Appendix 223
Methodology 223
Coverage 223
Secondary Research 223
Primary Research 223
Expert Panel Validation 223
Contact Us 224
Disclaimer 224

List of Tables
Number of Products under Development for Soft Tissue Sarcoma, H2 2014 11
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Comparative Analysis by Unknown Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Investigation by Universities/Institutes, H2 2014 22
Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 23
Soft Tissue Sarcoma - Pipeline by Activartis Biotech GmbH, H2 2014 24
Soft Tissue Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2014 25
Soft Tissue Sarcoma - Pipeline by Amgen Inc., H2 2014 26
Soft Tissue Sarcoma - Pipeline by Bayer AG, H2 2014 27
Soft Tissue Sarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 28
Soft Tissue Sarcoma - Pipeline by CASI Pharmaceuticals Inc., H2 2014 29
Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H2 2014 30
Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H2 2014 31
Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H2 2014 32
Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H2 2014 33
Soft Tissue Sarcoma - Pipeline by Gem Pharmaceuticals, LLC, H2 2014 34
Soft Tissue Sarcoma - Pipeline by GP Pharm, S.A., H2 2014 35
Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 36
Soft Tissue Sarcoma - Pipeline by MedImmune, LLC, H2 2014 37
Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H2 2014 38
Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H2 2014 39
Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H2 2014 40
Soft Tissue Sarcoma - Pipeline by Nanobiotix, H2 2014 41
Soft Tissue Sarcoma - Pipeline by Novartis AG, H2 2014 42
Soft Tissue Sarcoma - Pipeline by Oncos Therapeutics Ltd., H2 2014 43
Soft Tissue Sarcoma - Pipeline by Onxeo SA, H2 2014 44
Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H2 2014 45
Soft Tissue Sarcoma - Pipeline by Polaris Group, H2 2014 46
Soft Tissue Sarcoma - Pipeline by Recombio S.L, H2 2014 47
Soft Tissue Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2014 48
Soft Tissue Sarcoma - Pipeline by Telik, Inc., H2 2014 49
Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 50
Assessment by Monotherapy Products, H2 2014 51
Assessment by Combination Products, H2 2014 52
Number of Products by Stage and Target, H2 2014 54
Number of Products by Stage and Mechanism of Action, H2 2014 57
Number of Products by Stage and Route of Administration, H2 2014 59
Number of Products by Stage and Molecule Type, H2 2014 61
Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H2 2014 145
Soft Tissue Sarcoma - Dormant Projects, H2 2014 211
Soft Tissue Sarcoma - Discontinued Products, H2 2014 212